Product overview
Name | MDL 100907 |
Description | Potent and selective 5-HT2A receptor antagonist |
Alternative names | Volinanserin |
Purity | >98% |
Write Your Own Review
Biological Data
Biological description | Potent and selective 5-HT2A receptor antagonist (Ki = 0.36 nM). Shows > 80-fold selectivity for 5-HT2A over other 5-HT receptor subtypes. Displays antipsychotic actions. Active in vivo. |
Solubility & Handling
Storage instructions | +4°C |
Solubility overview | Soluble in DMSO (100 mM) and in 0.05M HCl (50 mM) |
Important | This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use. |
Chemical Data
Purity | >98% |
Chemical name | (R)-(+)-α-(2,3-Dimethoxyphenyl)-1-[2 -(4-fluorophenyl)ethyl]-4-piperinemethanol |
Molecular Weight | 373.46 |
Chemical structure | |
Molecular Formula | C22H28FNO3 |
CAS Number | 139290-65-6 |
PubChem identifier | 5311271 |
SMILES | COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O |
Source | Synthetic |
InChi | InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1 |
InChiKey | HXTGXYRHXAGCFP-OAQYLSRUSA-N |
MDL number | MFCD00909060 |
Appearance | White solid |
References for MDL 100907
References are publications that support the biological activity of the product
-
The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of dif
Ardayfio et al (2008) J Pharmacol Exp Ther 327(3) : 891-7 -
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne et al (1996) J Pharmacol Exp Ther 277(2) : 968-81 -
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
Sorensen et al (1993) J Pharmacol Exp Ther 266(2) : 684-91